Additional updates on the progression free survival data provide a future catalyst, with LPTX planning to provide updates in 2025. LPTX plans to run a phase 3 study of DKN-01 in colorectal cancer ...

Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Wednesday ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Investing.com -- Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(NASDAQ:LPTX) shares have tumbled to a 52-week low, touching down at $0.8 amidst a challenging market environment. With a market capitalization of just... ByInvesting.com • Jan 28, 2025 Leap ...